Advanced Filters
noise

Bergenfield, New Jersey Clinical Trials

A listing of Bergenfield, New Jersey clinical trials actively recruiting patient volunteers.

Found 1,382 clinical trials
R Randy Auerbach, PhD, ABPP

A Digitally Assisted Risk Reduction Platform for Youth at High Risk for Suicide

Despite efforts to prevent suicide, US rates are climbing, and suicide is the second leading cause of death among youth. Digital tools, especially personal smartphones, are promising avenues to address these issues and can be used to provide a unique understanding of risk factors, including psychological distress, anhedonia and behavioral …

13 - 18 years of age All Phase N/A
S Sujit S Nair, PhD

Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active Surveillance

This is a partially blinded randomized controlled phase II pilot study comparing Poly-ICLC (Hiltonol®) treatment vs no treatment, for prostate cancer participants on active surveillance.

18 years of age Male Phase 2

A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer

The purpose of this study is to see whether combining 2141-V11 with various standard treatments is an effective treatment approach for prostate cancer. 2141-V11 works by activating the immune system to find and kill cancer cells. Researchers will look at whether this treatment approach is able to completely get rid …

18 years of age Male Phase 2
M Melissa Hines, MD

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called …

1 - 21 years of age All Phase 2
J Joshua R. Cook, MD, PhD

Human Models of Selective Insulin Resistance: Alpelisib, Part I

The goal of this clinical trial is to understand how the blood sugar-lowering hormone insulin works in healthy adults versus those who are at risk for type 2 diabetes. The study will use a drug called alpelisib, which interferes with insulin's actions in the body, to answer the study's main …

18 - 70 years of age All Phase 1
R Rachel Maggi

Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel

To determine the safety and efficacy of GIE Medical's ProTractX3™ TTS DCB for the treatment of recurrent benign bowel strictures.

22 years of age All Phase 3

A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)

Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory to be changed (modified) to become 19-28z/IL-18, the CAR T-cell therapy that participants will receive during the study. Making the participants' …

17 years of age All Phase 1

Bimekizumab in Plaque Psoriasis

The purpose of this research study is to evaluate the effectiveness and safety of bimekizumab in individuals with moderate-to-severe psoriasis who have failed similar therapies. Bimekizumab improves psoriasis by suppressing a type of substance found in bodies called interleukins (specifically, interleukins 17a and 17F), which are known to increase inflammation. …

18 years of age All Phase 4
A Astrea Villarroel-Sanchez, MPH

Testosterone and Neural Function

Spinal cord injury (SCI) disrupts the nerves controlling movement, along with those that regulate functions like heart rate and blood pressure (known as the autonomic nervous system, or ANS). Testosterone (T) plays a significant role in brain health and ANS reflex function in non-neurologically impaired men. However, little is known …

18 - 80 years of age Male Phase N/A
J Jill Nicholas

Safety and Efficacy of GS-100 Gene Therapy in Patients With NGLY1 Deficiency

A non-randomized, open-label, dose escalation study of a single intracerebroventricular (ICV) administration of a gene replacement therapy in subjects who are 2 to 18 years old with NGLY1 Deficiency.

2 - 18 years of age All Phase 1/2

Simplify language using AI